Cargando…

Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib

The validity and relevance of histologic disease activity in Crohn’s disease (CD) is unclear, owing to disconnects with endoscopic pathology. Here, we explore relationships between endoscopic, histologic, and molecular activity. This post hoc analysis of the Phase 2 FITZROY trial (NCT02048618) asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reinisch, Walter, Serone, Adrian, Hébuterne, Xavier, Kühbacher, Tanja, Kłopocka, Maria, Roblin, Xavier, Brodbeck, Jens, Etchevers, Kim, Galien, René, Grant, Ethan, Tasset, Chantal, Yoon, Oh Kyu, Zaboli, Shiva, Vermeire, Séverine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161938/ https://www.ncbi.nlm.nih.gov/pubmed/35762272 http://dx.doi.org/10.1080/21688370.2022.2088961

Ejemplares similares

Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn’s Disease
por: Roblin, Xavier, et al.
Publicado: (2021)

Filgotinib: A Clinical Pharmacology Review
por: Namour, Florence, et al.
Publicado: (2022)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study
por: D’Haens, Geert R, et al.
Publicado: (2021)

Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor
por: Namour, Florence, et al.
Publicado: (2018)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
por: Genovese, Mark, et al.
Publicado: (2018)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial
por: Schreiber, Stefan, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
por: Namour, Florence, et al.
Publicado: (2015)

Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2020)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)
por: Maksymowych, Walter P, et al.
Publicado: (2021)

Let Food Be Thy Medicine—Its Role in Crohn’s Disease
por: Wellens, Judith, et al.
Publicado: (2021)

Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
por: Verstockt, Bram, et al.
Publicado: (2019)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Assessment of the Microbiota in Microdissected Tissues of Crohn's Disease Patients
por: De Hertogh, Gert, et al.
Publicado: (2012)

Mucosal microbial load in Crohn's disease: A potential predictor of response to faecal microbiota transplantation
por: Sarrabayrouse, Guillaume, et al.
Publicado: (2020)

Correction to: Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2021)

Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II
por: Reinisch, Walter, et al.
Publicado: (2021)

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
por: Tarrant, Jacqueline M., et al.
Publicado: (2020)

Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
por: Loftus, Edward V, et al.
Publicado: (2022)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
por: Balsa, Alejandro, et al.
Publicado: (2023)

MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases
por: Hellstrom, Wayne J. G., et al.
Publicado: (2022)

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study
por: Reinisch, Walter, et al.
Publicado: (2020)

Mucosal Interleukin‐10 depletion in steroid‐refractory Crohn's disease patients
por: Carrasco, Anna, et al.
Publicado: (2022)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Molecular Reclassification of Crohn's Disease by Cluster Analysis of Genetic Variants
por: Cleynen, Isabelle, et al.
Publicado: (2010)

Mucosal Barrier in Ulcerative Colitis and Crohn's Disease
por: Dorofeyev, A. E., et al.
Publicado: (2013)

NOD2 deficiency increases retrograde transport of secretory IgA complexes in Crohn’s disease
por: Rochereau, Nicolas, et al.
Publicado: (2021)

Understanding the Molecular Drivers of Disease Heterogeneity in Crohn’s Disease Using Multi-omic Data Integration and Network Analysis
por: Sudhakar, Padhmanand, et al.
Publicado: (2020)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial
por: Danese, Silvio, et al.
Publicado: (2023)

Association of a Functional Variant in the Wnt Co-Receptor LRP6 with Early Onset Ileal Crohn's Disease
por: Koslowski, Maureen J., et al.
Publicado: (2012)

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
por: Combe, Bernard, et al.
Publicado: (2022)

Diagnostic Difficulties in Woman with Crohn's Disease, Ascites, and Elevated Value of Serum CA125 Antigen
por: Kłopocka, Maria, et al.
Publicado: (2014)

Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease
por: Huang, Shanshan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tgugbf3fvof8g9vcl1at3o58t4